Clinical Application of New Biologics in Inflammatory Bowel Disease：Current Status and Future Prospect

doi:10.12114/j.issn.1007-9572.2021.00.519

Abstract

Abstract: Biologics such as anti-tumor necrosis factor-α agents have been increasingly used to treat inflammatory bowel disease（IBD）in recent years，but their clinical application are limited due to low safety and high rate of secondary loss of response.Currently，the treatment of IBD is entering into a biologics era as new types of biologics are emerging，in which they may become the main option in IBD pharmacological therapies.This paper reviewed the current application，mechanisms of action，therapeutic efficacy，safety and future prospect of new biologics for IBD，including anti-adhesion molecule agents，anti-IL-12/IL-23 agents and Janus kinase （JAK） inhibitors，providing a reference for the standardized and reasonable use of these new biologics in IBD.
Inflammatory bowel diseases；Biological factors；Inflammatory bowel disease；New biologics；Vedolizumab；Ustekinumab；Tofacitinib；Editorial

摘要： 近年来，抗肿瘤坏死因子α制剂等生物制剂在炎症性肠病（IBD）治疗方面的应用逐年增多，但由于其安全性较低且继发性失应答率较高等，临床应用受限。随着新型生物制剂不断涌现，IBD的治疗进入生物制剂时代，而新型生物制剂有可能成为IBD药物治疗的主体。本文就新型生物制剂抗黏附分子制剂、抗白介素12/23因子制剂及JAK抑制剂在IBD中的应用现状、作用机制、疗效、安全性及应用前景进行评述，以期为新型生物制剂在IBD患者中的规范、合理应用提供参考。

关键词: 炎性肠疾病, 生物因子, 炎症性肠病, 新型生物制剂, 维得利珠单抗, 乌司奴单抗, 托法替布, 述评

WANG Yingde. Clinical Application of New Biologics in Inflammatory Bowel Disease：Current Status and Future Prospect　[J]. Chinese General Practice, 2021, 24(21): 2629-2633. DOI: 10.12114/j.issn.1007-9572.2021.00.519.
王英德. 新型生物制剂在炎症性肠病中的临床应用：现状与未来[J]. 中国全科医学, 2021, 24(21): 2629-2633. DOI: 10.12114/j.issn.1007-9572.2021.00.519.

References

［1］TARGAN S R，HANAUER S B，VAN DEVENTER S J，et al．A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.Crohn's Disease cA2 Study Group［J］．N Engl J Med，1997，337（15）：1029-1035．DOI：10.1056/NEJM199710093371502.
［2］KARMIRIS K，PAINTAUD G，NOMAN M，et al．Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease［J］．Gastroenterology，2009，137（5）：1628-1640．DOI：10.1053/j.gastro.2009.07.062.
［3］BEN-HORIN S，CHOWERS Y.Review article：loss of response to anti-TNF treatments in Crohn's disease［J］．Aliment Pharmacol Ther，2011，33（9）：987-995．DOI：10.1111/j.1365-2036.2011.04612.x.
［4］DANESE S，FURFARO F，VETRANO S.Targeting S1P in inflammatory bowel disease：new avenues for modulating intestinal leukocyte migration［J］．J Crohns Colitis，2018，12（suppl_2）：S678-686．DOI：10.1093/ecco-jcc/jjx107.
［5］DASSOPOULOS T，SULTAN S，FALCK-YTTER Y T，et al．American Gastroenterological Association Institute technical review on the use of thiopurines，methotrexate，and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease［J］．Gastroenterology，2013，145（6）：1464-1478.e1-5．DOI：10.1053/j.gastro.2013.10.046.
［6］LICHTENSTEIN G R，FEAGAN B G，COHEN R D，et al．Serious infection and mortality in patients with Crohn's disease：more than 5 years of follow-up in the TREATTM registry［J］．Am J Gastroenterol，2012，107（9）：1409-1422．DOI：10.1038/ajg.2012.218.
［7］LICHTENSTEIN G R，RUTGEERTS P，SANDBORN W J，et al．
A pooled analysis of infections，malignancy，and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease［J］．Am J Gastroenterol，2012，107（7）：1051-1063．DOI：10.1038/ajg.2012.89.
［8］FEAGAN B G，RUTGEERTS P，SANDS B E，et al．Vedolizumab as induction and maintenance therapy for ulcerative colitis［J］．N Engl J Med，2013，369（8）：699-710．DOI：10.1056/NEJMoa1215734.
［9］SANDBRORN W J，FEAGAN B G，RUTGEERTS P，et al．Vedolizumab as induction and maintenance therapy for Crohn's disease［J］．N Engl J Med，2013，369（8）：711-721．DOI：10.1056/NEJMoa1215739.
［10］SOLER D，CHAPMAN T，YANG L，et al．The binding specificity and selective antagonism of vedolizumab，an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases［J］．J Pharmacol Exp Ther，2009，330（3）：864-875．DOI：10.1124/jpet.109.153973.
［11］WYANT T，LEACH T，SANKOH S，et al．Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract：randomised controlled trial results［J］．Gut，2015，64（1）：77-83．DOI：10.1136/gutjnl-2014-307127.
［12］FEAGAN B G，RUBIN D T，DANESE S，et al．Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis，regardless of prior exposure to tumor necrosis factor antagonists［J］．Clin Gastroenterol Hepatol，2017，15（2）：229-239.e5．DOI：10.1016/j.cgh.2016.08.044.
［13］COLOMBEL J，SANDS B E，RUTGEERTS P，et al．The safety of vedolizumab for ulcerative colitis and Crohn's disease［J］．Gut，2017，66（5）：839-851．DOI：10.1136/gutjnl-2015-311079.
［14］NEURATH M F.IL-23 in inflammatory bowel diseases and colon cancer［J］．Cytokine Growth Factor Rev，2019，45：1-8．DOI：10.1016/j.cytogfr.2018.12.002.
［15］FEAGAN B G，SANDBORN W J，GASINK C，et al．Ustekinumab as induction and maintenance therapy for Crohn's disease［J］．N Engl J Med，2016，375（20）：1946-1960．DOI：10.1056/NEJMoa1602773.
［16］LEE M J，PARKER C E，TAYLOR S R，et al．Efficacy of medical therapies for fistulizing Crohn's disease：systematic review and meta-analysis［J］．Clin Gastroenterol Hepatol，2018，16（12）：1879-1892．DOI：10.1016/j.cgh.2018.01.030.
［17］SANDBORN W，GASINK C，GAO L，et al．Ustekinumab induction and maintenance therapy in refractory Crohn's disease［J］．N Engl J Med，2012，367（16）：1519-1528．DOI：10.1056/NEJMoa1203572.
［18］BAR-GIL SHITRIT A，BEN-YA'ACOV A，SITERMAN M，et al．Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease：a multicenter Israeli study［J］．United European Gastroenterol J，2020，8（4）：418-424．DOI：10.1177/2050640620902956.
［19］BIEMANS V B C，VAN DER WOUDE C J，DIJKSTRA G，et al．
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment［J］．Aliment Pharmacol Ther，2020，52（1）：123-134．DOI：10.1111/apt.15745.
［20］SANDS B E，SANDBORN W J，PANACCIONE R，et al．Ustekinumab as induction and maintenance therapy for ulcerative colitis［J］．N Engl J Med，2019，381（13）：1201-1214．DOI：10.1056/NEJMoa1900750.
［21］OCHSENKüHN T，TILLACK C，SZOKODI D，et al．Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis［J］．United European Gastroenterol J，2020，8（1）：91-98．DOI：10.1177/2050640619895361.
［22］FERRANTE M，SABINO J.Efficacy of JAK inhibitors in ulcerative colitis［J］．J Crohns Colitis，2020，14（Supplement_2）：S737-745．DOI：10.1093/ecco-jcc/jjz202.
［23］GHORESCHI K，JESSON M I，LI X，et al．Modulation of innate and adaptive immune responses by tofacitinib（CP-690，550）［J］．J Immunol，2011，186（7）：4234-4243．DOI：10.4049/jimmunol.1003668.
［24］GHORESCHI K，LAURENCE A，O'SHEA J J，et al．Janus kinases in immune cell signaling［J］．Immunol Rev，2009，228（1）：273-287．DOI：10.1111/j.1600-065X.2008.00754.x.
［25］SANDBORN W J，SU C，PANES J，et al．Tofacitinib as induction and maintenance therapy for ulcerative colitis［J］．N Engl J Med，2017，377（5）：496-497．DOI：10.1056/NEJMoa1606910.
［26］WINTHROP K L，MELMED G Y，VERMEIRE S，et al．Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib［J］．Inflamm Bowel Dis，2018，24（10）：2258-2265．DOI：10.1093/ibd/izy131.
［27］SANDBORN W J，PANES J，D'HAENS G R，et al．Safety of tofacitinib for treatment of ulcerative colitis，based on 4.4 years of data from global clinical trials［J］．Clin Gastroenterol Hepatol，2019，17（8）：1541-1550．DOI：10.1016/j.cgh.2018.11.035.
［28］SANDBORN W J，GHOSH S，PANES J，et al．A phase 2 study of tofacitinib，an oral Janus kinase inhibitor，in patients with Crohn's disease［J］．Clin Gastroenterol Hepatol，2014，12（9）：1485-1493 e2．DOI：10.1016/j.cgh.2014.01.029.
［29］VERMEIRE S，SCHREIBER S，PETRYKA R，et al．Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib（the FITZROY study）：results from a phase 2，double-blind，randomised，placebo-controlled trial［J］．Lancet，2017，389（10066）：266-275．DOI：10.1016/S0140-6736（16）32537-5.
［30］MONTELEONE G，KUMBEROVA A，CROFT N M，et al．
Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease［J］．J Clin Invest，2001，108（4）：601-609．DOI：10.1172/JCI12821.
［31］MONTELEONE G，PALLONE F.Mongersen，an oral SMAD7 antisense oligonucleotide，and Crohn's disease［J］．N Engl J Med，2015，372（25）：2461．DOI：10.1056/NEJMc1504845.
［32］SANDS B E，FEAGAN B G，SANDBORN W J，et al．Mongersen（GED-0301）for active Crohn's disease：results of a phase 3 study［J］．Am J Gastroenterol，2020，115（5）：738-745．DOI：10.14309/ajg.0000000000000493.
［33］DANESE S，RODA G，PEYRIN-BIROULET L.Evolving therapeutic goals in ulcerative colitis：towards disease clearance［J］．Nat Rev Gastroenterol Hepatol，2020，17（1）：1-2．DOI：10.1038/s41575-019-0211-1.